Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.


Sharpen Your Pencil – And Put These Three Stocks on Your "Shopping List"

Ask any of our gurus for advice on how to survive a stock-market sell-off – or even a whipsaw period like the one we’re navigating now – and you’ll get a surprising answer.

Keep a shopping list ready, they’ll tell you…

  • biotech stocks

  • The Best Biotech Takeover Targets for 2014 cliff

    This could be the biggest year ever for investing in biotech takeover targets - all due to the patent cliff.

    The "patent cliff" refers to the sharp revenue drop a pharmaceutical company faces when the patent on one of its drugs expires. At that point, other drug companies can begin replicating name-brand drugs, cutting into the billions of dollars in revenue that large-cap pharmaceutical companies are used to.

    To continue reading, please click here...
  • IPO Calendar 2014 Dominated by Biotech best biotech investments 2014

    IPO Calendar 2014: This year is forecast to be a record year for initial public offerings (IPOs).

    Over the January to March period, some 250 to 300 new issues will launch, according to professional services firm EY - a number not seen since the start of the 2008 financial crisis.

    And biotech companies are the hottest issues to date.

    Since 2000, no two-week period saw more than six new biotech issues - until now.

    See which biotech IPOs could be the best investments now...
  • Furiex Pharmaceuticals (Nasdaq: FURX) Stock Up 130% Today on This "Blockbuster Drug" News

    While gains were modest across the three major benchmarks today (Tuesday), there was nothing modest about these major gains for Furiex Pharmaceuticals (Nasdaq: FURX) stock.

    Shares of Furiex more than doubled in value, surging some 150% intraday. The closed up 129.91% at $105.69. The reason: The company announced that its experimental drug eluxadoline significantly alleviated diarrhea and abdominal pain, which typically accompany irritable bowel syndrome (IBS), in two large late-stage trials.

    To continue reading, please click here...
  • Best Penny Stocks: Why Biotech Keeps Delivering Triple-Digit Gains best biotech investments 2014 Some of the top biotech penny stocks we recommended last year gained as much as 440%, 231%, and 214%. And the biotech sector is going to keep surging - especially the sector's best low-priced buys. We've already identified some of this year's winners - With that in mind, following are three of the best penny stocks in biotech.
  • Hot Penny Stocks This Week

    A number of this year's hot penny stocks have soared by double digits since the New Year.

    Their meteoric moves have far outpaced the lukewarm (if any) gains of major benchmarks and their components. The Dow is down roughly 4% and the S&P is off nearly 3% year to date, after gains of 26% and 32% respectively in 2013. The Nasdaq was up 1% until Friday's broad-based selloff left the tech-heavy index down an equal amount for the year.

    To continue reading, please click here...
  • Top Penny Stocks: How to Find Gains of 453% penny

    We're always looking for top penny stocks for investors - and some of our best picks climbed 440%, 231%, and 214% last year.

    Penny stock investing is always a tricky proposition. Pitfalls abound. Flaky financial reporting, the risk of securities fraud, and illiquidity are a few of the biggest concerns when investing in penny stocks.

    To continue reading, please click here...
  • The New Way to Make Big Money in Biotech Editor's Note: Today, we'd liked to welcome Ernie Tremblay to Money Morning. He's been providing his bioscience research to our premium services for over a year now and we couldn't be more thrilled with the results, including a 457% gain on one of his recommendations. So here's how Ernie does it...

    Traditional pharmaceutical blockbusters like Pfizer's Lipitor treat millions of patients at relatively low cost. It's a high-volume business model that has kept the pharmaceutical industry afloat for a long, long time. But over the past decade, out of necessity, a new model has taken the industry by storm.

    As big moneymakers, like Lipitor, reach the "patent cliff," their intellectual rights protection are evaporating, and generic drug makers are taking over their markets.

    Big Pharma needs fresh drugs to take the place of those they're losing. But replacing these products with new ones is expensive. Most experts agree that it takes about $800M in capitalized costs to develop a single new drug. And frankly, the "easier" medical riddles, like treating high LDL cholesterol, have mostly been solved. The remaining tough ones, like cancer and Alzheimer's, will drive costs even higher.

    So how do the major pharmaceutical companies meet the challenge? By letting small, smart start-up biotechs do the R&D legwork on new drugs, then either making distribution deals with them or buying the small companies out.

    Here's what makes this new approach so lucrative for investors...
  • Why Chelsea Therapeutics (Nasdaq: CHTP) Stock Is on Fire Lab worker Biotech has been the hot sector of late. Last week it was Intercept Pharma shooting up 280% in one day. This week it was a 92% gain for Chelsea Therapeutics. As more development-stage biotechs near approval for new treatments, We're going to see even more biotech rockets like Chelsea...
  • Why Intercept Pharma (Nasdaq: ICPT) Stock Gained 280% Today Drug bottles

    Yes, you're reading this correctly - Intercept Pharmaceuticals Inc. (Nasdaq: ICPT) stock more than tripled today (Thursday).

    ICPT shares surged 300% in trading today after an analysis by an independent safety committee showed its liver disease drug met the main goal of a mid-stage trial. ICPT stock closed at $275.49, up 280.56% from Wednesday's closing price of $72.39. The stock climbed as high as $305 in intraday trading.

    To continue reading, please click here...
  • I Just Got Another "Strong Buy" Signal… If you've been joining our twice-a-week get-togethers over at Strategic Tech Investor, you know that I'm a focused and disciplined investor - and that I ignore fads and refuse to chase "hot tips."

    I'm also very price-sensitive: Although I'm hunting for stocks capable of delivering "moonshot" price gains, I won't pay a penny more than my charts or "black box" system tells me they're worth.

    To enforce that discipline - and to help pass along to you all that I've learned through the years - I developed the set of five rules that we talk about here each week.

    But one of my best tools is also one of my simplest. It's a roster of companies whose stocks I'd someday like to own, but that don't currently meet my stringent criteria.

    I call it my "Watch List."

    And through the years, this simple shopping list for stocks has ended up delivering some of my all-time biggest winners...
  • Amgen (Nasdaq: AMGN) Deal Shows How to Find Biotech's Best Investments Microscope At $10.4 billion dollars, biotech giant Amgen's acquisition of Onyx is the fifth-largest biotech deal in history - and definitely won't be the last. This deal is a perfect illustration of why there’s so much money being made in biotech...


    To continue reading, please click here...
  • The Best New Companies In a White-Hot Sector Each of the companies you'll see today is just a few weeks old. That's why you need to know about them right now.

    You see, the market for all biotech shares is heating up.

    IPO action is proof of the big bucks coming into biotech, igniting a strong rally in the entire sector for the rest of the year. So far this year we've seen the most biotech IPOs in 13 years.

    And the gains are beginning to add up...

    The best-performing stock in this space, as you're about to see, is up 130% in little more than a month. And three other brand-new firms are roaring.

    But there's a better way to make money here... To continue reading, please click here...
  • Our Worry-Free Way of Investing in Biotech Handsome guy with arms behind head

    If there's one sector that's primed for explosive growth right now, it's biotechnology.

    Its position as a new market leader in the tech sector cannot be overstated. Clearly, investing in biotech is an idea few can afford to ignore.

    Genentech, the first biotech company, was formed in 1973 and was the first to go public in 1980, which launched the biotech sector.

    Though the sector is only 33 years old, humans have been using varying forms of biotech for thousands of years, before anyone was investing in anything.

    To continue reading, please click here...

  • The Best Biotech Stocks for 2013 Are Now Within Your Reach Medical pills small

    Biotech stocks are soaring in 2013 as major innovations in healthcare have offered enormous breakthroughs on once-untreatable diseases and conditions.

    But for years, it was tricky to invest in some of today's best biotech companies given their volatility and uncertainty in the industry. For the better part of five years, some of today's leading biotech stocks remained essentially flat.

    For some time, it was best to stick to large-scale pharmaceutical companies with a strong yield and avoid mass speculation in hit-or-miss penny stocks.

    Well, not any more. Shares of the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) - which tracks industry returns - are up a staggering 42% since the beginning of the year, and the health/biotech industry has the highest returns of any sector for the year.

    And you haven't seen anything yet...

    With one of the most exciting biotech companies now joining the NYSE and another setting its focus on an uplisting, we're seeing major changes in the biotech industry and investment. And there are companies poised to become the best biotech stocks you can find right now.

    To continue reading, please click here...

  • How to Invest in Biotech Now and Double Your Money Golden goblet

    Some of the most lucrative opportunities you can find now are in the biotechnology industry – which is why we've been working to uncover the best ways for how to invest in this sector.

    The best biotech companies overflow with innovation. They can offer a steady stream of game-changing products – which often translates to record-breaking revenue.

    The biotech industry is also known for its stiff competition. The race to be a consumer favorite causes companies to take big risks.

    Sometimes, these lead to embarrassing flops, but when they get it right, the payoffs are huge.

    That's a big reason why funding, often difficult to secure, is getting easier. Read more...